AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyNot reportedTrial registry
Study Invoking Human Subjects with MS Diagnosis
The study aims to confirm the diagnosis and subtype of multiple sclerosis (MS) by comparing tests on healthy individuals with those on patients who have immune-related CNS damage.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Establishing accurate diagnosis and understanding disease mechanisms could improve diagnostic tools and treatment strategies for MS and other CNS disorders.
What this does not prove
No results have been reported yet, and specific endpoints or planned enrollment details are not established, preventing conclusions from being drawn about the study's efficacy or outcomes.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- No
- Research areas
- Not classified
Original sources
Supporting passages (5)
subjectsThis study will include two groups of subjects at least 12 years old.
regulatory approval"isFdaRegulatedDevice": false
follow upAdult patients have a mandatory follow-up visit approximately 1-2 years from protocol enrollment.
findings"detailedDescription": "OBJECTIVE\n\nThe goal of this study is to define the pathophysiological mechanisms underlying the development of disability in immune-mediated disorders of the central nervous system (CNS) and to distinguish these from beneficial responses of the human immune system to CNS injury.\n\nThe protocol serves as a screening tool for Neuroimmunological Diseases Section (NDS) of the National Institute of Allergy and Infectious Diseases (NIAID) clinical trials and enables development of clinically-useful tools such as diagnostic tests and new, sensitive scales of neurological disability, disease severity and CNS tissue destruction.\n\nThis protocol also serves as a repository to enable prospective institutional review board (IRB) review of research using human samples and data collected under other NDS protocols.\n\nSTUDY POPULATION\n\nPatients with evidence, or suspicion of immune-mediated CNS injury.
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.